Skip to main content
. 2020 Jun;61(6):873–880. doi: 10.2967/jnumed.119.236059

TABLE 2.

Association of PTEN Immunohistochemistry Status with Clinical and Imaging Characteristics

PTEN status: per-patient analysis*
PTEN status: per-lesion analysis
Characteristic Loss Intact P Loss Intact P
n 36 39 38 65
Age (y) 69 (55–84) 71 (61–82) 0.179 NA NA
PSA (ng/mL) 18.1 (5.4–100.0) 12.3 (3.9–98.7) 0.424 NA NA
Prostate volume (cm3) 40.6 (18.7–91.5) 34.8 (12.6–110.9) 0.597 NA NA
Tumor diameter (cm) 2.1 (1.1–4.5) 2.1 (0.5–3.8) 0.330 2.1 (0.6–4.5) 1.2 (0.5–3.8) 0.106
GG
 1 0 (0.0) 6 (15.4) 0.202 (GG 1/2/3 vs. GG 4/5) 2 (5.3) 17 (26.2) 0.062 (GG 1/2/3 vs. GG 4/5)
 2 15 (41.7) 11 (28.2) 15 (39.5) 23 (35.4)
 3 10 (27.8) 15 (38.5) 10 (26.3) 16 (24.6)
 4 7 (19.4) 3 (7.7) 7 (18.4) 5 (7.7)
 5 4 (11.1) 4 (10.2) 4 (10.5) 4 (6.1)
pT stage NA NA
 2 11 (30.6) 14 (35.9) 0.624 (pT2 vs. pT3)
 3a 17 (47.2) 21 (53.8)
 3b 8 (22.2) 4 (10.3)
 4 0 (0.0) 0 (0.0)
pN stage 0.775 (pN0 vs. pN1) NA NA
 0 33 (91.7) 35 (89.7)
 1 3 (8.3) 4 (10.3)
 Visible on MRI 34 (94.4) 37 (94.9) 0.436 35 (92.1) 60 (92.3) 0.571
 Visible on PET 36 (100.0) 38 (97.4) 0.374 37 (97.4) 57 (87.0) 0.162
PI-RADS score
 3 0 (0.0) 3 (8.1) 0.313 (PI-RADS 3/4 vs. 5) 0 (0.0) 11 (18.3) 0.117 (PI-RADS 3/4 vs. 5)
 4 13 (38.2) 7 (18.9) 14 (40.0) 23 (38.3)
 5 21 (61.8) 27 (73.0) 21 (60.0) 26 (43.4)
ADCmean (μm2/s) 628.9 (462.4–724.3) 620.3 (402.1–867.78) 0.145 621.7 (462.4–735.0) 616.0 (402.1–904.0) 0.273
Maximum diameter (cm) 1.6 (0.8–4.3) 1.8 (0.4–3.8) 0.483 1.5 (0.8–4.3) 1.2 (0.5–3.8) 0.258
SUVmax 22.5 (7.7–41.3) 8.7 (3.5–28.2) <0.001 22.0 (6.9–41.3) 8.2 (3.5–28.2) <0.001

*Derived from index lesion on per-patient analysis.

P < 0.05.

NA = not applicable; PI-RADS = Prostate Imaging Reporting and Data System; maximum diameter = maximum diameter of lesion on MRI.

Categoric data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as median followed by range in parentheses.